Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. - Wikidata - awgldk - TriplyDB

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

http://www.wikidata.org/entity/Q50794115

about

Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation.A Multicenter Retrospective Analysis of Factors Associated With Apixaban-Related Bleeding in Hospitalized Patients With End-Stage Renal Disease on Hemodialysis.Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes.Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation.Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism.Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment: An Alternative Viewpoint.Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.What the non-nephrologist needs to know about dialysis.Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome.Balancing Anticoagulation Decisions in Patients on Dialysis with Atrial Fibrillation.Safety and effectiveness of apixaban compared to warfarin in dialysis patients Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges Successful treatment of heparin-induced thrombocytopenia with apixaban in a patient with chronic kidney disease requiring hemodialysis

P2860

Q38683015-DC88D553-8595-4EA7-A071-DA4687E96F9F Q38712570-F746135C-95F1-4F11-A987-46887B5140D8 Q47106586-3F081B5E-A3B6-4E65-A854-D7898267DF70 Q47365787-2FB49030-72AF-42EE-8BAB-3D977EEA5A36 Q47789803-2B7956DF-87B6-4090-9135-3A9D08CB5F63 Q48351747-4DB551D0-5320-4666-BEC4-58C4CDE0ECA4 Q50002162-15F4F81C-F689-4A60-8CE6-14B19F6985B0 Q50041154-D960A571-ACA2-4B4A-BD6D-D84F2A053085 Q55001247-2A28FEF9-1D3C-4CE8-80A1-9921966E98C2 Q55509896-6589BBB2-E583-404D-995E-B178E2F52D3B Q55522399-F40C7D9E-1BE9-48CD-88BB-5561AA0571B6 Q56380572-9F9A0CF4-2306-4EA9-8D29-417B8D2FA4B0 Q57625963-FDCF6B8E-588F-4DC6-B765-C00DE50747EF Q57750151-86F1A761-2752-4A5D-A1F0-8191DA5722E8 Q58578133-691A6DA8-0666-49A9-8807-8039607FA02C Q58749820-52BF1C3A-4822-4B20-B262-4F26244DB416 Q59130121-5BB8BA8F-61E5-4D92-B076-2ABE3397789C

P2860

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

http://www.wikidata.org/entity/Q50794115

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

@en

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

@nl

type

label

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

@en

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

@nl

prefLabel

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

@en

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

@nl

P1433

Q50794115-79FAC318-3E50-4C4D-82CB-75132B71BF2D

P1476

Q50794115-6FAEADC0-66B3-4266-81F9-6E7F0C7A3475

P2093

Q50794115-850067B2-1B6C-4886-A398-B45131292550

Q50794115-AF8ABAFD-BE97-4FBF-9379-C353AEE42991

Q50794115-C7DCFC7B-8F00-4427-8922-AF989956ED7E

Q50794115-E86C746A-20C8-460E-AA6C-C0A03F87DF2B

P2860

Q50794115-06D89BB8-C7FD-401B-A327-F7FE058985B6

Q50794115-24F25FEC-FF69-4BFD-A949-0911128F366A

Q50794115-3AF0A501-7FA9-466B-BCB7-1DC317BF1FA8

Q50794115-3CA16032-C968-4C84-BDE0-D3BE116820F8

Q50794115-3F21BE9B-DAC1-4EEF-A075-118B5E131019

Q50794115-46A2A8A2-8979-44A2-AC87-1AE804784D9C

Q50794115-48E7C545-EE27-4865-A0C0-A420BF78E683

Q50794115-54153979-E1F1-4DCC-B239-AB5612663D3D

Q50794115-54766161-CEB0-40AD-A420-4C53ED2A1BC6

Q50794115-5AB7797B-51A0-4B55-8DD5-564A2ECEAF53

P304

Q50794115-5E4FEBD4-8062-408D-9DFE-731FFF5BC3F2

P31

Q50794115-465106EE-379E-4178-875E-9F031941386E

P356

Q50794115-5361AF00-80B8-47F4-BDF0-4630E76F127C

P433

Q50794115-AE82F9AE-70E6-4464-A9F8-34BA2A7C008B

P478

Q50794115-D0DA2831-0B11-4DFB-8A31-AD5300FF047E

P50

Q50794115-B514CFAB-7F5C-4981-B986-7463034E4C25

P577

Q50794115-E94D547F-A372-4064-809C-A504E36C2B11

P698

Q50794115-CC7FF67B-D0AA-488A-BA1A-0817279A06E3

P932

Q50794115-9E5475DE-2DA8-46D2-93D2-B901C120E7F5

P356

P1433

Journal of the American Society of Nephrology

P1476

Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients.

@en

P2093

Caroline F Samer

http://www.w3.org/2001/XMLSchema#string

Gershon Frisch

http://www.w3.org/2001/XMLSchema#string

Mark L Lipman

http://www.w3.org/2001/XMLSchema#string

Sharon J Nessim

http://www.w3.org/2001/XMLSchema#string

P2860

Direct oral anticoagulants: efficacy and safety in patient subgroups

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulat

Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Apixaban versus warfarin in patients with atrial fibrillation

Apixaban metabolism and pharmacokinetics after oral administration to humans.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.

The increasing prevalence of atrial fibrillation among hemodialysis patients.

Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.

Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation.

P304

2241-2248

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2016090980

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Mavrakanas

P577

2017-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28302754

http://www.w3.org/2001/XMLSchema#string

P932

5491286

http://www.w3.org/2001/XMLSchema#string